Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  The Lancet

• Publication date

  2017-06-10

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S0140-6736(17)31429-0PMID 28551073
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Short‐ and long‐term safety outcomes with ixekizumab from 7 clinical trials in psoriasis: Etanercept comparisons and integrated data

  2017cited by this paper
• Psoriatic Arthritis.

  2017cited by this paper
• Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1

  2016cited by this paper
• Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis.

  2016cited by this paper
• Generation and characterization of ixekizumab, a humanized monoclonal antibody that neutralizes interleukin-17A

  2016cited by this paper
• A Highly Sensitive and Drug-Tolerant Anti-Drug Antibody Screening Assay for Ixekizumab using Affinity Capture Elution.

  2016cited by this paper
• Radiographic Progression of Patients With Psoriatic Arthritis Who Achieve Minimal Disease Activity in Response to Golimumab Therapy: Results Through 5 Years of a Randomized, Placebo‐Controlled Study

  2016cited by this paper
• Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis.

  2016cited by this paper
• Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis

  2016cited by this paper
• Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials.

  2015cited by this paper
• European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update

  2015cited by this paper
• Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis.

  2015cited by this paper
• A short history of biological therapy for psoriatic arthritis.

  2015cited by this paper
• Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial.

  2015cited by this paper
• Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis.

  2014cited by this paper
• Interleukin-17+CD8+ T Cells Are Enriched in the Joints of Patients With Psoriatic Arthritis and Correlate With Disease Activity and Joint Damage Progression

  2014cited by this paper
• Pathogenic role of IL-17 in psoriasis and psoriatic arthritis.

  2014cited by this paper
• Group for Research and Assessment of Psoriasis and Psoriatic Arthritis - GRAPPA (2003-2013).

  2013cited by this paper
• Interleukin-17-positive mast cells contribute to synovial inflammation in spondylarthritis.

  2012cited by this paper
• IL-17 signaling in host defense against Candida albicans

  2011cited by this paper
• Abatacept in the treatment of patients with psoriatic arthritis: results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial.

  2011cited by this paper
• Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy

  2010cited by this paper
• Validation of minimal disease activity criteria for psoriatic arthritis using interventional trial data

  2010cited by this paper
• Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment

  2009cited by this paper
• Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study.

  2009cited by this paper
• Treatment recommendations for psoriatic arthritis

  2008cited by this paper
• Increased numbers of circulating polyfunctional Th17 memory cells in patients with seronegative spondylarthritides.

  2008cited by this paper
• Classification criteria for psoriatic arthritis: development of new criteria from a large international study.

  2006cited by this paper
• Psoriatic arthritis therapy: NSAIDs and traditional DMARDs

  2005cited by this paper
• Psoriatic arthritis: epidemiology, clinical features, course, and outcome

  2005cited by this paper
• Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial.

  2005cited by this paper
• Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression.

  2004cited by this paper
• PSORIATIC ARTHRITIS.

  1965cited by this paper

• Comparative effectiveness and persistence of ixekizumab and other b/tsDMARDs in patients with PsA from a real-world setting: 12-month results from the PRO-SPIRIT study

  2026cites this paper
• Ixekizumab for the treatment of psoriatic arthritis: an Italian multicentric retrospective observational study

  2026cites this paper
• Cycling or Swapping in Spondyloarthritis? Current Knowledge

  2026cites this paper
• The Relative Effects of Monotherapies for Psoriatic Nails: A Network Meta‐Analysis Study

  2026cites this paper
• IL-17A in psoriatic arthritis: mechanistic insights, clinical implications, and advances in therapeutic strategies

  2025influential citation
• Longer Drug Retention of Interleukin-12/23 or Interleukin-17 Inhibitors Compared With TNF Inhibitors in Female Patients With TNF Inhibitor-Experienced Psoriatic Arthritis

  2025cites this paper
• Biologic of choice after secukinumab failure in psoriatic arthritis patient: Ixekizumab or interleukin-23 inhibitors – A retrospective study

  2025cites this paper
• Phage therapy as a revitalized weapon for treating clinical diseases

  2025cites this paper
• Therapeutic Windows Across the Psoriatic Arthritis Spectrum

  2025cites this paper
• Novel pharmacotherapies and breakthroughs in psoriatic arthritis treatment

  2025cites this paper
• New Toxicity Signals Associated With Ixekizumab.

  2025cites this paper
• Ixekizumab Retention Rate and Predictors of Treatment Persistence in Psoriatic Arthritis: Results of an Italian Multicenter Study

  2025cites this paper
• Synergistic Improvements in Synovitis, Enthesitis, and Patient-Reported Outcomes for Patients with Psoriatic Arthritis Treated with Ixekizumab in SPIRIT Trials

  2025cites this paper
• Precision medicine using molecular-target drugs in psoriatic arthritis

  2025cites this paper
• Advances in treatment of psoriatic arthritis: current guidelines and emerging therapies.

  2025cites this paper
• Effectiveness of ixekizumab in 709 real-world patients with axial spondyloarthritis and psoriatic arthritis: a nationwide cohort study

  2025cites this paper
• One-year retention rate of ixekizumab in patients with psoriatic arthritis and axial spondyloarthritis: Real-world data from the BIOBADASER registry.

  2025cites this paper
• Real-World Evidence for Ixekizumab in the Treatment of Psoriasis, Psoriatic Arthritis, and Axial Spondyloarthritis: Systematic Literature Review 2022–2023

  2025cites this paper
• Towards new approach methodologies for biological therapeutics: a novel model-informed metric to assess immunogenicity risk

  2025cites this paper
• Inflammation-Driven Molecular Ageing in Chronic Inflammatory Skin Diseases: Is There a Role for Biologic Therapies?

  2025cites this paper
• Efficacy and safety of IL-17, IL-12/23, and IL-23 inhibitors for psoriatic arthritis: a network meta-analysis of randomized controlled trials

  2025cites this paper
• Circulating CD8 T cells from patients with mild-to-moderate psoriasis are functionally impaired

  2025cites this paper
• The relationship between circulating and tissue biomarkers and OA-related pain: A systematic literature review

  2025cites this paper
• The Role of IL-17A in Mediating Inflammatory Responses and Progression of Neurodegenerative Diseases

  2025cites this paper
• Detailed assessment of axial and peripheral entheses and joints in axial spondyloarthritis and psoriatic arthritis patients treated with ixekizumab (DAPHNE): design of a 2-year phase IV trial applying whole-body MRI, MRI-based synthetic CT, and CT

  2025cites this paper
• Unveiling Sex-Related Variability in Psoriatic Arthritis: A Call for Personalized Care

  2025cites this paper
• Efficacy of Biological or Targeted Synthetic Disease‐Modifying Anti‐Rheumatic Drugs in Active Psoriatic Arthritis: A Network Meta‐Analysis of Randomized Controlled Trials

  2025cites this paper
• Safety and effectiveness of ixekizumab in Japanese patients with psoriasis vulgaris, psoriatic arthritis, generalized pustular psoriasis, and erythrodermic psoriasis: Post‐marketing surveillance

  2025cites this paper
• Efficacy and safety of izokibep in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study.

  2025cites this paper
• From the Masterclasses in Dermatology 2024 Meeting: Updates in Psoriasis Treatments.

  2025cites this paper
• Expert Opinion Report on the Challenges in the Management of Psoriatic Arthritis in United Arab Emirates: A Focus on Interleukin-17 Inhibitors

  2025cites this paper
• Identification of JNJ-61803534, a RORγt Inverse Agonist for the Treatment of Psoriasis.

  2025cites this paper
• Therapeutic efficacy of molecular-targeted drugs for enthesitis in patients with PsA: a network meta-analysis

  2025cites this paper
• IL-17 as a Therapeutic Target in Cardiovascular Diseases: Mechanistic Insights and Translational Opportunities.

  2025cites this paper
• Risk of Malignancy Related to Ixekizumab in Patients With Psoriatic Arthritis or Axial Spondyloarthropathy

  2024cites this paper
• Advances in the management of psoriatic arthritis in adults

  2024cites this paper
• Infections in psoriatic arthritis: association with treatment

  2024cites this paper
• Unintended Consequences of Immune Therapy for Immune-Mediated Diseases: Paradoxical Psoriasis and Dupilumab-Associated Musculoskeletal Syndrome.

  2024cites this paper
• Injection site reactions resulting from the use of biological therapy in the treatment of moderate-to-severe plaque psoriasis

  2024cites this paper
• Treatment controversies in spondyloarthritis and psoriatic arthritis: focus on biologics and targeted therapies

  2024cites this paper
• Comparative early effectiveness across 14 PsA drugs and 5 classes of PsA treatment: 3-month results from the PRO-SPIRIT study

  2024cites this paper
• Filling the “GAP” in Real-World Assessment of Psoriatic Arthritis Disease Activity: Performance Characteristics of a Global/Pain Composite Endpoint

  2024cites this paper
• Ixekizumab Demonstrates Rapid and Consistent Efficacy for Patients with Psoriatic Arthritis, Regardless of Psoriasis Severity

  2024cites this paper
• Exploring the Effects of Ixekizumab on Pain in Patients with Ankylosing Spondylitis Based on Objective Measures of Inflammation: Post Hoc Analysis from a Large Randomized Clinical Trial

  2024cites this paper
• Real‐World Treatment Patterns, Clinical Outcomes, and Symptom Burden in Patients With Psoriatic Arthritis Prescribed Ixekizumab in the United States

  2024cites this paper
• Phage Display Technology in Biomarker Identification with Emphasis on Non-Cancerous Diseases

  2024cites this paper
• Residual Disease Activity in Canadian Patients With Psoriatic Arthritis Treated With Advanced Therapies: Results From a Multiregistry Analysis (UNISON-PsA)

  2024cites this paper
• Retention Rate of Ixekizumab in Psoriatic Arthritis: A Real-World Study

  2024cites this paper
• Evaluating the inhibition of IL-17A and TNFα in a cartilage explant model cultured with Th17-derived cytokines

  2024cites this paper
• Difficult-to-treat psoriatic arthritis (D2T PsA): a scoping literature review informing a GRAPPA research project

  2024cites this paper
• Hot Topics: Depression in Individuals With Psoriasis and Psoriatic Arthritis.

  2024cites this paper
• Long-term safety of Ixekizumab in adults with psoriasis, psoriatic arthritis, or axial spondyloarthritis: a post-hoc analysis of final safety data from 25 randomized clinical trials

  2024cites this paper
• State of the Art Review on the Treatment of Psoriatic Disease

  2024cites this paper
• Targeting cytokines in psoriatic arthritis.

  2024cites this paper
• Effects of secukinumab and ixekizumab on major adverse cardiovascular events in patients with psoriasis: a meta-analysis of randomized controlled trials

  2024cites this paper
• Psoriatic disease and non-alcoholic fatty liver disease shared pathogenesis review.

  2023cites this paper
• Adverse events associated with anti-IL-17 agents for psoriasis and psoriatic arthritis: a systematic scoping review

  2023cites this paper
• Treatment Retention and Safety of Ixekizumab in Psoriatic Arthritis: A Real Life Single-Center Experience

  2023cites this paper
• Real-world evidence for ixekizumab in the treatment of psoriasis and psoriatic arthritis: literature review 2016–2021

  2023cites this paper
• Impact of targeted therapies on the risk of cardiovascular events in patients with psoriasis and psoriatic arthritis: A systematic review and aggregate data meta‐analysis of randomized controlled trials

  2023cites this paper
• Chronic Recurrent Multifocal Osteomyelitis (CRMO) and Juvenile Spondyloarthritis (JSpA): To What Extent Are They Related?

  2023cites this paper
• The evolving demographics of participants in psoriatic arthritis phase III randomised controlled trials of b/tsDMARDs: A systematic review.

  2023cites this paper
• Phenotypic heterogeneity in psoriatic arthritis: towards tissue pathology-based therapy

  2023cites this paper
• A Systematic Review Evaluating the Effectiveness of Several Biological Therapies for the Treatment of Skin Psoriasis

  2023cites this paper
• Short-term risk and long-term incidence rate of infection and malignancy with IL-17 and IL-23 inhibitors in adult patients with psoriasis and psoriatic arthritis: a systematic review and meta-analysis

  2023cites this paper
• Risk of infections in psoriatic arthritis or axial spondyloarthritis patients treated with biologic or targeted therapies: a meta-analysis of randomized controlled trials.

  2023cites this paper
• Systematic literature review and network meta-analysis of therapies for psoriatic arthritis on patient-reported outcomes

  2023cites this paper
• Ixekizumab Efficacy in Patients with Severe Peripheral Psoriatic Arthritis: A Post Hoc Analysis of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study (SPIRIT-P1)

  2023influential citation
• Sex-related differences in patient characteristics, and efficacy and safety of advanced therapies in randomised clinical trials in psoriatic arthritis: a systematic literature review and meta-analysis.

  2023cites this paper
• Unintentional unblinding in rheumatic disease trials.

  2023cites this paper
• Effect of guselkumab on serum biomarkers in patients with active psoriatic arthritis and inadequate response to tumor necrosis factor inhibitors: results from the COSMOS phase 3b study

  2023cites this paper
• The effect of ixekizumab on axial manifestations in patients with psoriatic arthritis from two phase III clinical trials: SPIRIT-P1 and SPIRIT-P2

  2023cites this paper
• Pharmacologic Treatment Strategies in Psoriatic Arthritis.

  2023cites this paper
• Inflammatory Cytokines in Psoriatic Arthritis: Understanding Pathogenesis and Implications for Treatment

  2023cites this paper
• Ixekizumab for Active Radiographic Axial Spondyloarthritis in Chinese Patients: 16- and 52-Week Results from a Phase III, Randomized, Double-Blind, Placebo-Controlled Study

  2023cites this paper
• Real-World Persistence and Treatment Patterns in Patients with Psoriatic Arthritis Treated with Anti-IL17 Therapy in Spain: The PerfIL-17 Study

  2023cites this paper
• Comparative short-term risks of infection and serious infection in patients receiving biologic and small-molecule therapies for psoriasis and psoriatic arthritis: a systemic review and network meta-analysis of randomized controlled trials

  2023cites this paper
• Bimekizumab for the treatment of psoriatic arthritis

  2023cites this paper
• Assessing Comparative Efficacy of Biologics for the Treatment of Psoriasis With Nail Involvement: A Systematic Review

  2023cites this paper
• Safety of current systemic therapies for nail psoriasis

  2023cites this paper
• Consensus on targeted drug therapy for spondyloarthritis

  2023cites this paper
• Changes in musculoskeletal disease activity and patient-reported outcomes in patients with psoriatic arthritis treated with ixekizumab: results from a real-world US cohort

  2023cites this paper
• Efficacy and Safety of Nail Psoriasis Targeted Therapies: A Systematic Review

  2023influential citation
• Anti-IL17 treatment in childhood chronic rheumatic diseases

  2023cites this paper
• The efficacy and safety of ixekizumab in the treatment of spondyloarthritis under the conditions of real clinical practice

  2023cites this paper
• Real‐World Evidence Assessing Psoriatic Arthritis by Disease Domain: An Evaluation of the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry

  2023cites this paper
• Expert Perspective: Management of the Psoriatic Arthritis Patient After Failure of One Tumor Necrosis Factor Inhibitor

  2023cites this paper
• Guselkumab, a Selective Interleukin‐23 p19 Subunit Inhibitor, Resolves Dactylitis in Patients With Active Psoriatic Arthritis: Pooled Results Through Week 52 From Two Phase 3 Studies

  2023cites this paper
• Targeted Therapies in Psoriatic Arthritis—An Update

  2023cites this paper
• Emerging treatment options for psoriatic arthritis

  2023cites this paper
• Psoriatic Arthritis: Pathogenesis and Targeted Therapies

  2023cites this paper
• A Comprehensive Review of Ixekizumab Efficacy in Nail Psoriasis from Clinical Trials for Moderate-to-Severe Psoriasis and Psoriatic Arthritis

  2023cites this paper
• KAJIAN PUSTAKA: BIOMARKER DIAGNOSIS DAN THARGETED THERAPHY PSORIATIC ARTHRITIS

  2023cites this paper
• Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE).

  2022cites this paper
• What’s new and what’s next for biological and targeted synthetic treatments in psoriatic arthritis?

  2022cites this paper
• The Clinical Significance of Simultaneous IL-17A and IL-17F Blockade in Psoriasis Non-Responding to Anti-IL17A Therapy

  2022cites this paper
• Treatment of Psoriasis in Patients With Psoriatic Arthritis: An Updated Literature Review Informing the 2021 GRAPPA Treatment Recommendations

  2022cites this paper
• Patient and Physician Global Assessments of Disease Status in Systemic Sclerosis

  2022cites this paper
• English version of Japanese guidance for use of biologics for psoriasis (the 2022 version)

  2022cites this paper
• Why targeted therapeutics have provided benefit in psoriasis: looking at IL-17 biology

  2022cites this paper